Results 91 to 100 of about 18,044 (238)

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge

European Medical Journal Rheumatology, 2018
Biosimilars are more affordable versions of previously approved biopharmaceuticals that are designed to reduce healthcare expenditure and increase patient access to this therapeutic class. To achieve their economic potential, many European countries have
Filipe C. Araújo, Joao Eurico Fonseca, Joao Goncalves   +2 more
doaj  

Factors that Influence Healthcare Professionals' Intentions towards Biosimilars

INNOVATIONS in Pharmacy
Background: Physicians often prescribe original biologic products to patients who have not used them before and are reluctant to switch to biosimilars.
Mohammed Alqahtani, Ahmed Al-Jedai, Albert Wertheimer   +2 more
doaj   +1 more source

Bioloogiliste ravimite uus julge maailm: ravimiarenduse edasiminekud viimase viie aasta jooksul [PDF]

, 2011
Eesti Arst 2011; 90(7):338 ...
Harrison, Pille, Irs, Alar, Laius, Ott
core   +2 more sources

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Regulatory justifications: regulating European medicines to maximise market potential [PDF]

, 2016
The justification for regulating is generally considered to rely on benefitting interested groups. Whereas the traditional view is that regulators act as impartial arbiters balancing competing public and private interests, modern accounts consider ...
Warren-Jones, A.
core   +1 more source

Investigating the Effect of Tumour Necrosis Factor Antagonist on Olfaction

Clinical Otolaryngology, EarlyView.
ABSTRACT Objectives Tumour Necrosis factor antagonists is a potent anti‐inflammatory medication and has shown to improve olfactory function in murine models. The primary aim was to determine the effect of TNF antagonists on olfactory performance in humans.
Andreas Espehana, George Macfarlane, Elizabeth Mairenn Garden, Liam Lee, Gabija Klyvyte, Lavandan Jegatheeswaran, Rebecca Davies, Carl Philpott   +7 more
wiley   +1 more source

Biosimilars

Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems.
Tabernero, Josep||, Vyas, Malvika, Giuliani, Rosa, Arnold, Dirk||, Cardoso, Fatima, Casali, Paolo Giovanni||, Cervantes, Andrés||, Eggermont, Alexander||, Eniu, Alexandru, Jassem, Jacek, Pentheroudakis, George||, Peters, Solange, Rauh, Stefan, Zielinski, Christoph C., Stahel, Rolf A., Voest, Emile||, Douillard, Jean-Yves||, McGregor, Keith, Ciardiello, Fortunato   +18 more
openaire   +3 more sources

Biosimilars in rheumatology: what the clinician should know

RMD Open, 2015
Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars ...
Jonathan Kay, Gilberto Castañeda-Hernández, Rodrigo González-Ramírez, Morton A Scheinberg   +3 more
doaj   +1 more source

Adoption of biosimilar infliximab for rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel diseases in the EU5: A budget impact analysis using a Delphi panel [PDF]

, 2017
Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn's disease and ulcerative colitis) may reduce treatment costs associated with ...
Arnold G. Vulto, Isabelle Huys, Jelena Stevanovic, Jelena Stevanovic, Steven Simoens, Tim A. Kanters   +5 more
core   +5 more sources